| CR1 (N = 33) | CR > 1 (N = 75) | PR (N = 90) | Refractory (N = 38) | ||||
---|---|---|---|---|---|---|---|---|
Outcomes | N | Prob (95% CI) | N | Prob (95% CI) | N | Prob (95% CI) | N | Prob (95% CI) |
NRM | 33 | Â | 75 | Â | 90 | Â | 38 | Â |
1-year |  | 6 (1–17)% |  | 20 (12–30)% |  | 20 (13–29)% |  | 24 (12–38)% |
2-year |  | 13 (4–26)% |  | 29 (19–40)% |  | 25 (17–35)% |  | 30 (16–45)% |
3-year |  | 17 (6–32)% |  | 31 (21–43)% |  | 25 (17–35)% |  | 30 (16–45)% |
4-year |  | 17 (6–32)% |  | 36 (25–49)% |  | 33 (22–44)% |  | 30 (16–45)% |
Progression/ relapse | 33 | Â | 75 | Â | 90 | Â | 38 | Â |
1-year |  | 15 (5–29)% |  | 13 (7–22)% |  | 14 (7–21)% |  | 29 (16–44)% |
2-year |  | 25 (12–41)% |  | 16 (9–26)% |  | 19 (11–28)% |  | 29 (16–44)% |
3-year |  | 25 (12–41)% |  | 18 (10–28)% |  | 19 (11–28)% |  | 32 (18–48)% |
4-year |  | 25 (12–41)% |  | 18 (10–28)% |  | 21 (12–30)% |  | 32 (18–48)% |
PFS | 33 | Â | 75 | Â | 90 | Â | 38 | Â |
1-year |  | 79 (63–91)% |  | 67 (56–77)% |  | 66 (56–76)% |  | 47 (32–63)% |
2-year |  | 62 (45–78)% |  | 54 (43–66)% |  | 56 (45–66)% |  | 41 (26–57)% |
3-year |  | 58 (41–75)% |  | 50 (38–62)% |  | 56 (45–66)% |  | 38 (23–54)% |
4-year |  | 58 (41–75)% |  | 45 (33–58)% |  | 47 (36–58)% |  | 38 (23–54)% |
Overall survival | 33 | Â | 75 | Â | 90 | Â | 38 | Â |
1-year |  | 88 (75–97)% |  | 73 (63–83)% |  | 71 (61–80)% |  | 63 (47–78)% |
2-year |  | 78 (62–90)% |  | 62 (51–73)% |  | 59 (48–69)% |  | 52 (36–67)% |
3-year |  | 70 (52–85)% |  | 58 (46–70)% |  | 57 (47–68)% |  | 52 (36–67)% |
4-year |  | 70 (52–85)% |  | 54 (41–66)% |  | 50 (39–62)% |  | 52 (36–67)% |